Tiziana's Experimental MS Treatment Meets Main Goals in Mid-Stage Study
Tiziana said its experimental multiple sclerosis treatment met the main goals in a mid-stage study.
Related stories
IDEXX Executive Says Covet Revenue Run Rate Is About $20 Million
An IDEXX executive said Covet revenue is growing at strong double-digit rates.
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Infineon and Qualcomm Technologies Sign Automated Driving Agreement
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Fox Shares Rise After Q1 Results Top Estimates
Fox shares rise after first-quarter results top estimates, supported by advertising.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
AAR Proposes $955 Million and $960 Million Senior Note Offerings
AAR proposed $955 million of senior notes due 2031 and $960 million of senior notes due 2034.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
Teva shares fall after rare brain disorder drug trial halted
US-listed shares of Israel-based Teva fell after a trial of a drug for a rare brain disorder was halted.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
Fox Q1 results beat on advertising strength
Fox shares rose after the company reported Q1 results that beat expectations, citing advertising strength.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC